NuWays rates Eckert & Ziegler stock Buy with EUR 21.50 target
Published on 10/13/2026 at 10:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- NuWays rates Eckert & Ziegler stock Buy with a EUR 21.50 target on October 13, 2026.
- First-half 2026 revenue reached EUR 149.3 million, while net income rose to EUR 22.4 million.
- The stock was trading at EUR 12.44 at Lang & Schwarz on October 13, 2026, plus 0.81 percent versus the Xetra close of EUR 12.34 on October 12, 2026.
- Eckert & Ziegler's next reported earnings date is November 12, 2026.
NuWays rated Eckert & Ziegler stock Buy and set a EUR 21.50 12-month target on October 13, 2026, according to TradingView. The target is 72.83 percent above the EUR 12.44 price at Lang & Schwarz, while the stock was 0.81 percent above the Xetra close of EUR 12.34 on October 12, 2026. The combination puts the research call beside a market price still close to the lower end of the recent range.
NuWays sees independent supply value
NuWays said Eckert & Ziegler's independent isotope supply and specialist manufacturing capacity gain strategic value as radiopharmaceutical businesses consolidate. The research identified contract development and manufacturing as an operating driver, with sales in that business nearly doubling in the first half of 2026 and adding EUR 3.1 million year over year, according to TradingView.
The research also highlighted manufacturing quality as a commercial factor for drug developers. That view matters because Eckert & Ziegler supplies medical isotopes without competing directly with customers' drug portfolios, giving the company a distinct position within the radiopharmaceutical supply chain.
Three dated operating milestones
On March 26, 2026, Eckert & Ziegler reported historical fiscal-year 2025 revenue of EUR 312.0 million and adjusted EBIT of EUR 77.7 million, according to Marketscreener. On August 13, 2026, first-half revenue reached EUR 149.3 million versus EUR 148.8 million a year earlier, while net income rose to EUR 22.4 million from EUR 21.4 million, according to wallstreetONLINE. On October 13, 2026, NuWays published its EUR 21.50 target and Buy recommendation, according to TradingView.
What does the target imply?
The target would require a 72.83 percent rise from EUR 12.44, a large valuation gap that makes execution more important than the headline rating. Eckert & Ziegler confirmed 2026 guidance for revenue of EUR 320.0 million and adjusted EBIT of EUR 80.0 million after the first-half result, according to wallstreetONLINE.
Next reporting date is November 12
The next scheduled company reporting date is November 12, 2026, when Eckert & Ziegler is listed to publish its third-quarter financial report, according to wallstreetONLINE. That report should show whether the first-half revenue comparison of EUR 149.3 million versus EUR 148.8 million is carrying into the second half.
Stock remains near its yearly low
Eckert & Ziegler was trading at EUR 12.44 at Lang & Schwarz on October 13, 2026 at 10:29 a.m. CEST, up 0.81 percent versus the Xetra close of EUR 12.34 on October 12, 2026. The finance quote showed a 52-week range of EUR 11.91 to EUR 17.73 and market capitalization of EUR 779.7 million as of October 13, 2026.
The further course of trading is shown by the continuously updated real-time quote of Eckert & Ziegler stock.
Eckert & Ziegler stock facts
- Company: Eckert & Ziegler SE
- ISIN: DE0005659700
- WKN: 565970
- Ticker: EUZ
- Primary exchange: Xetra
- Price Lang & Schwarz (as of October 13, 2026, 10:29 a.m. CEST): EUR 12.44
- Change versus Xetra close: plus 0.81 percent
- Xetra close (October 12, 2026): EUR 12.34
- Market capitalization: EUR 779.7 million (as of October 13, 2026)
- 52-week range: EUR 11.91-EUR 17.73 (as of October 13, 2026)
- Sector / Industry: Health care / medical equipment
- Index membership: TecDAX
- Next earnings date: November 12, 2026
Market context: Market report DAX.
